First patient included into ISR’s Phase IIa HIV study
As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.ISR’s Phase IIa clinical study, ISR-003, is conducted at the Karolinska University Hospital Huddinge and at the South Hospital in Stockholm, SÖS. The study is composed of two arms with a total of 26+26 patients to be randomized into ART+ISR048 or to ART alone in the control group. Patients will be treated for 3 months and then followed for an